Handelsavisen
prelaunch
Companies Healthcare MNOV.NS
MN
MNOV.NS NSE (India) Pharmaceuticals & Medical Research

Manoj Vaibhav Gems N Jewellers Ltd

$155,48
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
6,7 %
ROE
3,3 %
Net margin
3,8 %
Debt / equity
0,69
Beta
52w range
Volume
136
Day range
$1,32–$1,35
Prev close
$1,33
Open
$1,32
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

Manoj Vaibhav Gems N Jewellers Ltd operates in the retail sector, specializing in the sale of gems and jewelry, generating revenue primarily through direct sales to consumers.

Business. Manoj Vaibhav Gems N Jewellers Ltd (MNOV.NS) is an Indian retailer operating within the Consumer Cyclicals sector, specifically classified under Apparel & Accessories Retailers. The company is primarily listed on the National Stock Exchange of India. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the business is described at the industry level as a product-sale retailer without further operational breakdown.

Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY4 analysts
4 buy0 hold0 sell
Avg 12m price target9,00

Analyst recommendations

4 analysts · consensus Buy
Buy4
Hold0
Sell0
12-month price target
9,00
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
4 analysts · indicative
Ownership
UBS Financial Services, Inc.
largest disclosed fund holder
Profitability
3,3 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning MNOV.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to MNOV.NS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Manoj Vaibhav Gems N Jewellers Ltd (MNOV.NS) is an Indian retailer operating within the Consumer Cyclicals sector, specifically classified under Apparel & Accessories Retailers. The company is primarily listed on the National Stock Exchange of India. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the business is described at the industry level as a product-sale retailer without further operational breakdown.

    Classification99 %
    SectorHealth Care
    Industry groupPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    Manoj Vaibhav Gems N Jewellers Ltd maintains a debt-to-equity ratio of 0.69, indicating a moderate reliance on debt financing, while its current ratio of 1.83 suggests reasonable short-term liquidity. The company's operating cash flow of INR 595.1 million supports its capital expenditures of INR -15.31 million, indicating a net outflow for capital investments.

    In terms of profitability, the company reports a return on equity of 3.33% and a return on assets of 1.47%, both of which are below the typical thresholds for strong performance in the retail sector. These figures suggest that the company is generating modest returns relative to its equity and asset base.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification, which may expose it to regional economic fluctuations. There is no information provided on the geographic distribution of its revenue, making it difficult to assess the extent of regional concentration risk.

    The company's growth trajectory is not clearly defined, as there is no outlook data provided for the current or next fiscal year. However, the operating income of INR 366.91 million and net income of INR 205.65 million indicate a stable but not rapidly growing business.

    The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could impact its ability to meet short-term obligations without additional financing. There are no specific dilution sources identified, and the dilution risk is assessed as low.

    Recent events and filings have not been disclosed in the available data, so there is no information on recent strategic moves, earnings calls, or regulatory actions that could impact the company's performance.

    Key takeaways
    • The company maintains a moderate debt-to-equity ratio and a reasonable current ratio, indicating a balanced capital structure.
    • Return on equity and return on assets are below typical performance benchmarks for the retail sector.
    • Revenue is concentrated in a single business segment, with no geographic diversification disclosed.
    • Growth is stable but not rapid, with no clear outlook for the next fiscal year.
    • Liquidity risk is assessed as medium, and dilution risk is low.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 4

    Revenue grew at a 13.6% CAGR over four years, reaching INR 23.8 billion in the latest fiscal period.

    Net income surged with a 48.3% CAGR over four years, demonstrating strong bottom-line expansion capabilities.

    Cash conversion ratio of 2.89 ranks in the top quartile compared to the cohort median of 1.26.

    Long-term debt decreased from INR 4.3 billion in FY-1 to INR 4.0 billion in FY0.

    BEAR CASE · 2

    The company carries a high credit risk flag, indicating potential solvency or repayment concerns.

    Debt-to-equity ratio of 0.69 is higher than the 0.34 median for the Apparel & Accessories cohort.

    In focus — financials by report

    Valuation FY

    Market price
    $155,48
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $6.18B
    Net cash
    -$4.29B
    Current ratio
    1.8
    Debt / equity
    0.7
    ROA
    1.5%
    ROE
    3.3%
    Cash conversion
    289.0%
    CapEx / revenue
    -0.3%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryPharmaceuticals & Medical Research15,2B node revenueKLAR 23,0%BNTX 21,4%EXEL 15,2%MDGL 6,3%INSM 4,0%VCYT 3,4%MDXG 2,8%AVIR 2,3%Other 21,6%
    Source: company disclosures · own-taxonomy revenue-covered set · attribution: collision-suspect (indicative)MNOV 0,0% · rank #83 of 109

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs MNOV · multiples and returns
    KL
    KLAR
    KLAR.ST
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    BN
    BNTX
    Biontech SE
    $92,25
    23,3B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    EX
    EXEL
    Exelixis Inc
    $55,06
    14,7B USD
    P/E
    19,5x
    vs self
    Div yield
    vs self
    ROE
    40,4 %
    +69,3 vs self
    MD
    MDGL
    Madrigal Pharmaceuticals Inc
    $482,00
    11,0B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -47,8 %
    -19,0 vs self
    IN
    INSM
    Insmed Inc
    $107,46
    23,0B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -160,2 %
    -131,3 vs self
    VC
    VCYT
    Veracyte Inc
    $45,30
    3,6B USD
    P/E
    55,5x
    vs self
    Div yield
    vs self
    ROE
    5,1 %
    +33,9 vs self
    MD
    MDXG
    Mimedx Group Inc
    $4,27
    636,0M USD
    P/E
    11,1x
    vs self
    Div yield
    vs self
    ROE
    18,9 %
    +47,8 vs self
    AV
    AVIR
    Atea Pharmaceuticals Inc
    $4,61
    P/E
    vs self
    Div yield
    vs self
    ROE
    -57,5 %
    -28,6 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -0,30
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    4
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-16 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$6,00
    Mean$9,00
    Median$9,50
    High$11,00
    Spot$155,48
    −94.2 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin6,7 %Above P75
    Net Margin3,8 %Above P75
    ROE3,3 %Above median
    Capex / Rev-0,3 %Above median
    D/E0,69Bottom quartile
    Cash Conv2,89Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 933 500 sh5 grants5 insiders
    • Lemerond NicoleDirector · Stock Option (Right to Buy) → Common StockAcquired 44 500 @ $1,36grant · 2026-06-23
    • BEAVER CAROLYNDirector · Stock Option (Right to Buy) → Common StockAcquired 44 500 @ $1,36grant · 2026-06-23
    • Nagao HidekiDirector · Stock Option (Right to Buy) → Common StockAcquired 44 500 @ $1,36grant · 2026-06-23
    • Matsuda KazukoChief Medical Officer · Employee Stock Option (Right to Buy) → Common StockAcquired 350 000 @ $2,10grant · 2026-01-16
    • IWAKI YUICHIPresident and CEO · Employee Stock Option (Right to Buy) → Common StockAcquired 450 000 @ $2,10grant · 2026-01-16

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Manoj Vaibhav Gems N Jewellers Ltd Market data — financials · 2026-05-28

    Ownership & reference

    Top holders

    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$1M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$1M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$0M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$0M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$1M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$0M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$0M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Insider activity

    — missing data

    Short positioning

    310.4Kshares short+51.5% vs prior
    4.26days to cover
    22.4%short of daily vol
    1.0Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    MNOV.NSCanonical
    NSE (India) · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    • Net margin (FY 2025-12-31): 2,928.8%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -4.3%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -4.3%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 19.1%Derived (calculated)
    • Return on equity (FY 2025-12-31): 28.9%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): -18.4%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -20.8%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): -1.5%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -4.8%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 7.8%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): 8.6%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -23.7%Derived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): 223.9%Derived (calculated)
    • Debt-to-equity (FY 2025-12-31): 0.10xDerived (calculated)
    • Current ratio (FY 2025-12-31): 8.16xDerived (calculated)
    • Return on assets (FY 2025-12-31): 26.3%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2023-12-31): -59.0%Derived (calculated)
    • EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing
    • EPS (diluted) (annual): USD-PER-SHARES -0SEC XBRL filing
    • R&D expense (annual): USD 6.7MSEC XBRL filing
    • Operating income (annual): USD -13.28MSEC XBRL filing
    • Operating cash flow (annual): USD -9.81MSEC XBRL filing
    • Total liabilities (annual): USD 4.02MSEC XBRL filing
    • Cash & equivalents (annual): USD 30.81MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-23 00:00 UTCINSIDER3 insider transactions — 2026-06 3 derivative
    2026-06-23INSIDERLemerond Nicole acquired 44.5k sh Stock Option (Right to Buy) — Director
    2026-06-23INSIDERNagao Hideki acquired 44.5k sh Stock Option (Right to Buy) — Director
    2026-06-23INSIDERBEAVER CAROLYN acquired 44.5k sh Stock Option (Right to Buy) — Director
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-05-14FILING10-Q filing →
    2026-04-29FILINGDEF 14A filing →
    2026-03-10FILING10-K filing →
    2026-02-20FILING8-K filing →
    2026-01-16 00:00 UTCINSIDER2 insider transactions — 2026-01 2 derivative
    2026-01-16INSIDERIWAKI YUICHI acquired 450.0k sh Employee Stock Option (Right to Buy) — President and CEO
    2026-01-16INSIDERMatsuda Kazuko acquired 350.0k sh Employee Stock Option (Right to Buy) — Chief Medical Officer
    2025-12-30FILING424B5 filing →
    2025-12-30FILING8-K filing →
    2025-11-12FILING10-Q filing →
    2025-08-22FILINGS-1 filing →
    2025-08-14FILING10-Q filing →
    2025-08-01FILING8-K filing →
    2025-06-18FILING8-K filing →
    2025-06-17 00:00 UTCINSIDER3 insider transactions — 2025-06 3 derivative
    2025-05-13FILING10-Q filing →
    2025-02-12 00:00 UTCINSIDER5 insider transactions — 2025-02 5 derivative
    2025-01-07 00:00 UTCINSIDER2 insider transactions — 2025-01 2 derivative
    2024-06-11 00:00 UTCINSIDER3 insider transactions — 2024-06 3 derivative
    2024-01-09 00:00 UTCINSIDER3 insider transactions — 2024-01 3 derivative
    2023-08-04 00:00 UTCINSIDER1 insider transaction — 2023-08 1 derivative
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage